Atricure, Inc. (ATRC) Stock Price & Analysis
Atricure, Inc. (ATRC) rose 1.43% to USD 27.3 as of June 10, 2026 at 03:44 UTC, according to Nexqual real-time market data.
ATRC last closed at USD 26.92; the session ranged USD 26.84–27.63 on volume of 570,498 shares. Market capitalization is $1.38B, with a 52-week range of USD 25.36–43.18 (NGM). Source: Nexqual, June 10, 2026 at 03:44 UTC.
Key Statistics (as of June 10, 2026 at 03:44 UTC)
| Price | USD 27.3 |
|---|---|
| Change | ▲ 1.43% (up) |
| Previous Close | USD 26.92 |
| Open | USD 26.96 |
| Day Range | USD 26.84 – 27.63 |
| 52-Week Range | USD 25.36 – 43.18 |
| Volume | 570,498 shares |
| Market Cap | $1.38B |
| Exchange | NGM |
Technical Analysis (ATRC)
Nexqual's technical model rates ATRC "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 48.84 (neutral) |
| vs SMA50 | Below (USD 28.09) |
| MACD | -0.39 (negative) |
Analyst Ratings (ATRC)
Wall Street analysts rate ATRC "None" based on 8 analysts, with a mean price target of USD 47 (range USD 36–55), per Nexqual as of June 10, 2026 at 03:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 47 |
| High Target | USD 55 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (ATRC)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 0.02 |
| Revenue Estimate | $151.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.06 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.12 ▲ beat |
| 2025-06-30 | USD -0.02 vs est -0.16 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financials & Fundamentals (ATRC)
| Total Revenue | $552.16M |
|---|---|
| Revenue Growth (YoY) | +14.30% |
| Gross Margin | +75.61% |
| Operating Margin | +0.37% |
| Profit Margin | -0.83% |
| ROE | -0.97% |
| Debt / Equity | 15.24 |
| Current Ratio | 4.29 |
| Total Cash | $146.16M |
| Total Debt | $74.91M |
| Free Cash Flow | $41.06M |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financial Health Score (ATRC)
Nexqual rates Atricure, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 03:44 UTC.
| Growth | Solid — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 0% |
| Balance Sheet | Strong — $146M cash vs $75M debt, net cash position |
| Cash Flow | Solid — FCF $41M, 8% margin |
| Efficiency | Critical — ROE -1%, ROA -0.3% |
Ownership (ATRC)
| Insider Ownership | +3.85% |
|---|---|
| Institutional Ownership | +102.37% |
| Shares Outstanding | 50.64M |
| Float | 48.55M |
| Short % of Float | +6.99% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Leadership (ATRC)
Atricure, Inc. is led by Michael H. Carrel (age 54), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:44 UTC.
| CEO, President & Director | Michael H. Carrel (age 54) |
|---|---|
| Chief Financial Officer | Angela L. Wirick (age 47) |
| Chief Operating Officer | Douglas J. Seith (age 59) |
| Chief Marketing & Strategy Officer | Justin J. Noznesky (age 47) |
| Chief Scientific Officer | Vinayak Doraiswamy (age 52) |
Major Backers & Investors (ATRC)
Notable institutional backers of Atricure, Inc. include Wellington Management, Alliancebernstein L.P., Hood River Capital Management LLC, according to Nexqual as of June 10, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 6.68% |
| Alliancebernstein L.P. | 6.44% |
| Hood River Capital Management LLC | 6.16% |
| Nomura Asset Management International Inc | 3.56% |
| Goldman Sachs | 3.29% |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 3.02% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.93% |
| Marshall Wace LLP | 2.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.05% |
| BlackRock | 10.22% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
From Atricure, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
- It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
- In addition, the company sells various reusable cardiac surgery instruments.
- It markets and sells its products through independent distributors and direct sales personnel.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANGO | AngioDynamics, Inc. | USD 12.34 | ▲ 3.35% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| LMAT | LeMaitre Vascular, Inc. | USD 96.59 | ▲ 2.23% |
| AXGN | AxoGen, Inc. | USD 42.87 | ▲ 0.16% |
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:44 UTC. This page is informational and not investment advice.